Agilon Health, Inc. (NYSE:AGL) Receives Consensus Rating of “Hold” from Analysts

Shares of Agilon Health, Inc. (NYSE:AGL) have been assigned a consensus rating of “Hold” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $2.60.

Several equities analysts recently weighed in on AGL shares. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Royal Bank Of Canada raised shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Wells Fargo & Company upped their target price on shares of Agilon Health from $1.00 to $1.50 and gave the company an “overweight” rating in a report on Friday. Barclays reduced their price target on Agilon Health from $1.00 to $0.50 and set an “underweight” rating for the company in a report on Friday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st.

Agilon Health Price Performance

Shares of NYSE:AGL opened at $0.59 on Monday. The company’s 50-day moving average price is $0.71 and its two-hundred day moving average price is $0.85. Agilon Health has a one year low of $0.34 and a one year high of $6.08. The stock has a market capitalization of $243.94 million, a PE ratio of -0.62 and a beta of 0.06.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 100.06% and a negative net margin of 6.60%.The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.46 billion. On average, analysts anticipate that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilon Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGL. CenterBook Partners LP boosted its holdings in shares of Agilon Health by 492.4% during the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after buying an additional 9,499,012 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Agilon Health by 1,028.9% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 789,703 shares of the company’s stock worth $1,816,000 after acquiring an additional 719,751 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Agilon Health by 2.6% during the second quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock worth $16,462,000 after acquiring an additional 178,477 shares during the period. SG Americas Securities LLC grew its position in shares of Agilon Health by 60.1% in the second quarter. SG Americas Securities LLC now owns 230,912 shares of the company’s stock valued at $531,000 after purchasing an additional 86,723 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Agilon Health by 583.2% in the second quarter. XTX Topco Ltd now owns 400,760 shares of the company’s stock valued at $922,000 after purchasing an additional 342,100 shares during the last quarter.

Key Stories Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Wells Fargo upgraded AGL to “overweight” and raised its price target to $1.50 (from $1.00), implying meaningful upside from current levels — a bullish analyst signal that can support buying interest. Benzinga
• Neutral Sentiment: Q4 results were mixed: revenue beat estimates ($1.57B vs. ~$1.46B) but EPS missed materially (reported ($0.46) vs. consensus ($0.27)), leaving investors weighing top-line strength against profitability issues. Earnings Release/Transcript
• Neutral Sentiment: Management outlined a 2026 target (~$5.5B revenue and breakeven adjusted EBITDA) as part of a transformation plan — a constructive medium‑term goal but one that may be viewed skeptically given recent misses and execution risk. Seeking Alpha
• Negative Sentiment: Company guidance was lower than Street expectations (FY revenue midpoint and Q1 revenue below consensus), which increases downside risk as analysts rework models and investor confidence is tested. Seeking Alpha
• Negative Sentiment: Barclays cut its price target to $0.50 and moved to “underweight,” signaling additional analyst pessimism and potential further selling pressure. Benzinga
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in securities class actions alleging fraud tied to Agilon, with several deadline reminders for March 2, 2026 — legal overhang and potential litigation costs are weighing on sentiment. GlobeNewswire

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.